Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Loading
Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Calendar quarter Q2 2026Earnings call Aug 4, 2026 · most recent call
PFE’s newest analyzed quarter is part of Tellvest Pro: its score, breakdown, narrative and analyst Q&A. Every prior quarter is free.
Sources. Scores: Pfizer’s public earnings-call transcripts and SEC-reported results — the base band is anchored to reported GAAP revenue growth; transcript, EPS and guidance adjustments are applied separately (documented exceptions apply to a few issuers). Price: PFE daily closing prices for the trailing year; dots mark earnings calls, colored by that quarter’s score; the newest quarter’s score is part of Tellvest Pro. How to read a company earnings-call score.
All prior quarters are free. How to browse earnings-call scores without Pro. How to read a company earnings-call score.
The breakdown for this quarter is part of Tellvest Pro.
Full Pro access for 30 days when you create a free account. No credit card required.
The table scrolls sideways. Swipe it, or select it and use the arrow keys.
| Quarter | Revenue | Rev YoY | EPS | EPS YoY | Net margin | FCF |
|---|---|---|---|---|---|---|
| FY2024 Q4 | $17.76B | +21.9% | $0.07 | +112.1% | 2.3% | $5.80B |
| FY2025 Q1 | $13.71B | -7.8% | $0.52 | -5.1% | 21.6% | $1.77B |
| FY2025 Q2 | $14.65B | +10.3% | $0.51 | — | 19.9% | $-1.20B |
| FY2025 Q3 | $16.65B | -5.9% | $0.62 | -20.9% | 21.3% | $4.00B |
| FY2025 Q4 | $17.56B | -1.2% | $-0.29 | -503.3% | -9.4% | $4.50B |
| FY2026 Q1 | $14.45B | +5.4% | $0.47 | -9.5% | 18.6% | $2.18B |
| FY2026 Q2Selected | $15.03B | +2.6% | $-0.04 | -108.5% | -1.6% | $302M |
Management-stated figures from PFE’s newest call are part of Tellvest Pro.
No 8-K events recorded since this call day.